• Tacrine Hydrochloride Hydrate: Assay Logic

  2026-08-17

  Tacrine hydrochloride hydrate is more than a historical cholinesterase inhibitor: it is a controlled perturbation tool for dissecting cholinergic signaling, neuroprotection, and assay translation. This guide connects molecular mechanism with practical endpoint selection while defining what the compound can—and cannot—prove in Alzheimer’s disease research.

• 1-methyl Adenosine: Assay Workflows

  2026-08-16

  Turn 1-methyl Adenosine into a practical readout for RNA turnover, cancer metabolism studies, and biomarker discovery. This guide pairs careful sample handling with stable isotope-diluted UHPLC-MS/MS, emphasizing isomer resolution, matrix control, and troubleshooting.

• Irinotecan Workflows for Tumor Microenvironment Assays

  2026-08-15

  Use Irinotecan (CPT-11) as a mechanistic challenge compound for linking topoisomerase I stress to viability, DNA damage, and apoptosis across colorectal cancer models. Matched organoid–stromal assembloids add a practical layer for testing how tumor microenvironment context changes drug sensitivity and resistance.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-08-14

  This guide explains how to use Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, for HMGB1 detection in Western blot, immunohistochemistry, and flow cytometry workflows. It is a research-use reagent for human, mouse, and rat samples and should not be treated as a diagnostic or therapeutic assay component.

• MG-132 and the m6A–Proteasome Axis

  2026-08-14

  MG-132 is a cell-permeable proteasome inhibitor that can do more than trigger apoptosis: it can help test how m6A-dependent RNA regulation connects to ubiquitin-mediated proteostasis. This article develops an ovarian-aging assay framework grounded in the YTHDF2/UBE3C study while distinguishing mechanistic inference from established evidence.

• 2-APB for Calcium Signaling Workflows

  2026-08-13

  2-APB provides a practical way to separate IP3 receptor-mediated calcium release from downstream store-operated calcium entry and channel effects. This workflow guide combines concentration-aware assay design with reference-study insights for calcium signaling, oxidative injury, and cardiovascular research.

• ATRX Loss Sensitizes Glioma Cells to PDGFR Inhibitors

  2026-08-13

  The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that ATRX status may help interpret RTK inhibitor trials and guide studies combining targeted inhibition with temozolomide.

• Isorhamnetin as a PI3K/Akt Assay Probe

  2026-08-12

  Isorhamnetin is a flavonoid research compound that links PI3K/Akt activation with oxidative stress, endoplasmic reticulum stress, and apoptosis in porcine oocytes. This article translates the reference findings into practical assay decisions while defining the limits of cross-model interpretation.

• Partial BACE Inhibition and Synaptic Transmission

  2026-08-12

  Satir et al. examined whether reducing amyloid-β production through partial β-secretase inhibition disrupts synaptic transmission in primary cortical neurons. Their results indicate that Aβ secretion can fall by up to approximately 50% without measurable synaptic impairment in this model, whereas stronger inhibition reduced both Aβ secretion and synaptic transmission.

• AP-2α Suppresses MGMT in Recurrent GBM

  2026-08-11

  The reference study identifies AP-2α as a transcriptional suppressor of MGMT in recurrent glioblastoma and links this pathway to improved temozolomide-induced DNA damage. Its combination of promoter-mapping assays, resistant glioma models, and intracranial validation provides a mechanistic framework for studying TMZ resistance and MGMT-directed sensitization.

• P2RX1, CaMKII, and Mitochondrial Apoptosis in Ph+ ALL

  2026-08-11

  Li et al. identify P2RX1 as a regulator of tyrosine kinase inhibitor-induced mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. Their data connect calcium imbalance and CaMKII activation with suppression of PI3K/Akt survival signaling, providing a mechanistic framework for studying treatment response and possible resistance in Ph+ ALL.

• Oligomycin A in Mitochondrial Bioenergetics

  2026-08-10

  Oligomycin A provides a direct way to separate ATP-linked respiration from glycolytic compensation, making it valuable in cancer metabolism research and immune-cell assays. This workflow-focused guide covers dose finding, oxygen-consumption measurements, ROS and apoptosis readouts, and the limitations of extending mitochondrial perturbation into tumor-associated macrophage biology.

• Lenalidomide in Myeloma Research: Workflow & Insights

  2026-08-09

  Build more informative myeloma experiments with Lenalidomide (CC-5013), combining immune, antiproliferative, and angiogenesis readouts instead of relying on viability alone. This workflow translates recent DOT1L–innate immunity findings into practical combination designs, controls, and troubleshooting decisions.

• LY294002 Workflow for PI3K–Mitophagy Studies

  2026-08-08

  Learn how to use LY294002 to interrogate PI3K/Akt/mTOR control of mitophagy, pyroptosis, and inflammatory cartilage injury. This practical guide combines pathway controls, assay-ready parameters, comparative interpretation, and troubleshooting for disease and cancer models.

• LY-411575 Gamma-Secretase Inhibitor Workflows

  2026-08-07

  LY-411575 enables controlled interrogation of amyloid beta production and Notch cleavage in cell-based and translational research workflows. Its sub-nanomolar potency is especially useful when Aβ measurements are paired with NICD, viability, or functional neuronal readouts to separate pathway modulation from nonspecific toxicity.

16331 records 1/1089 page Next 12345 下5页 Last page